Consumer Legal Funding Didn’t Add $4 Billion to Malpractice Losses

The claim and why it matters

A recent Medical Economics story reports that inflation, “economic and social”, added $4 billion to medical-malpractice insurer losses over the last decade, based on a study by The Doctors Company (with Moore Actuarial). The article highlights “large verdicts” and “litigation financing” among contributing forces. The press release and accompanying analysis from The Doctors Company say the $4 billion figure equals roughly 11% of booked losses for the decade ending in 2024, up from the company’s prior estimate for the decade ending in 2021.[1]

First principles: what CLF is (and isn’t)

Consumer legal funding (CLF) provides small, non-recourse funds to individuals with pending claims to help with living expenses (rent, utilities, groceries) while their case proceeds. Repayment, if any, comes from the claimant’s recovery; if the case fails, the consumer owes nothing. Critically, CLF does not finance the litigation itselfit is not a war chest for lawyers, discovery, or expert fees. That distinction is reflected in statutes, such as those in Oklahoma and Utah, which prohibit funders from paying court costs, filing fees, or attorney fees.[2]

What the $4 billion estimate actually says

The Doctors Company attributes the $4 billion to a mix of economic inflation (rising medical costs, wages, and services) and social inflation (jury attitudes, verdict norms, legal environment). Its materials mention “litigation financing” as one item among many within social inflation; they do not quantify the share attributable to financing, let alone to consumer funding specifically. The estimate is a blended actuarial inference, not a direct causal measurement.[3]

The data gap problem: we can’t blame what we can’t measure

Even for commercial litigation finance—where transactions are larger—the U.S. Government Accountability Office (GAO) has emphasized data gaps. GAO’s 2022 report found limited visibility into total funding volumes, returns, and the extent of financing across case types. If policymakers lack robust market data even for institutional funding, it is implausible that anyone can credibly ascribe a precise portion of malpractice losses to consumer funding, which is smaller, more diffuse, and often regulated at the state level.[4]

Causation vs. correlation—and why CLF’s mechanics matter

To say that “financing exists and verdicts are higher” confuses correlation with causation. CLF does not finance litigation activities, it operates at a small, individual scale, and any apparent association with higher payouts reflects selection bias—funders prefer meritorious cases, which would likely recover more regardless.[2]

What plausibly explains the $4 billion

If CLF isn’t the driver, what is? The Doctors Company itself points to economic inflation in health care, large verdicts and changing valuation norms, rising defense costs, and demographic pressures as the main causes. Each has a direct actuarial footprint, while none requires CLF to explain the 11% uplift.[3]

Don’t conflate markets: commercial funding ≠ consumer funding

When headlines mention “litigation financing,” they often track commercial activity—law-firm portfolio deals or corporate disputes worth billions annually. That is a separate market for a few thousand dollars to injured individuals. Rolling those into one bucket and blaming consumer funding for malpractice loss trends is misleading.[5]

Policy takeaway: precision beats generalizations

Good policy requires accurate taxonomy and evidence. If studies believe commercial funding contributes to higher awards, they should measure that and not attribute it to CLF. The GAO flagged the scarcity of reliable data, and until we have case-level evidence, attributing malpractice cost increases to CLF is unjustified.[4]

Bottom line

The $4 billion estimate is about inflation in general, not about consumer legal funding. CLF doesn’t pay attorneys, experts, or filing fees; it helps individuals cover basic needs. The real drivers are medical price inflation, jury award norms, and systemic cost growth. Until researchers isolate consumer funding and prove a causal link, the fair conclusion is that CLF did not add $4 billion to malpractice losses.[1][2][3][4][5]

References

[1] Medical Economics; The Doctors Company press release and actuarial analysis.

[2] State statutes and legislative materials (Oklahoma, Kentucky) defining and limiting consumer legal funding.

[3] The Doctors Company, ‘Social Inflation and Loss Development’ reports.

[4] U.S. Government Accountability Office, 2022 report on Third-Party Litigation Finance.

[5] Westfleet Advisors, ‘Litigation Finance Market Snapshot’ (commercial funding data).